This study aimed to review the clinical features and outcome of 53 patients with solitary plasmacytoma managed at our Institution between 1976 and 2012. Thirty-five patients had bone solitary plasmacytoma and 18 extramedullary solitary plasmacytoma. Tumour sizes were larger in patients with bone involvement (P=0·003). Treatment consisted of local radiotherapy (n=26), radiotherapy+chemotherapy (n=15), surgery (n=4) and chemotherapy (n=8); the local control rate was 94·3%. Progression to multiple myeloma was recorded in 20/35 (57·1%) patients with bone involvement and in 1/18 (5·5%) patients with extramedullary disease (P=0·0003). The 5-year overall survival (OS) rate was 78·4%; bone solitary plasmacytoma patients had a significantly worse OS (71·9% vs. 88·2%, respectively; P=0·029) and 5-year progression-free survival (PFS; 53·0% vs. 88·5%; P=0·0003) compared to extramedullary solitary plasmacytoma patients. On univariate analysis, bone disease and size (≥5cm) impacted negatively on PFS (P=0·0027 and P=0·04, respectively). Bone disease also affected OS (P=0·04). In multivariate analysis bone location was the only independent prognostic factor for PFS (P=0·0041) and OS (P=0·021). Patients with bone solitary plasmacytoma have a significantly worse prognosis than extramedullary solitary plasmacytoma cases.
Clinical features and prognostic factors in solitary plasmacytoma / Finsinger, Paola; Grammatico, Sara; Chisini, Marta; Piciocchi, Alfonso; Foa, Roberto; Petrucci, MARIA TERESA. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 172:4(2016), pp. 554-560. [10.1111/bjh.13870]
Clinical features and prognostic factors in solitary plasmacytoma
GRAMMATICO, SARA;CHISINI, MARTA;FOA, Roberto;PETRUCCI, MARIA TERESA
2016
Abstract
This study aimed to review the clinical features and outcome of 53 patients with solitary plasmacytoma managed at our Institution between 1976 and 2012. Thirty-five patients had bone solitary plasmacytoma and 18 extramedullary solitary plasmacytoma. Tumour sizes were larger in patients with bone involvement (P=0·003). Treatment consisted of local radiotherapy (n=26), radiotherapy+chemotherapy (n=15), surgery (n=4) and chemotherapy (n=8); the local control rate was 94·3%. Progression to multiple myeloma was recorded in 20/35 (57·1%) patients with bone involvement and in 1/18 (5·5%) patients with extramedullary disease (P=0·0003). The 5-year overall survival (OS) rate was 78·4%; bone solitary plasmacytoma patients had a significantly worse OS (71·9% vs. 88·2%, respectively; P=0·029) and 5-year progression-free survival (PFS; 53·0% vs. 88·5%; P=0·0003) compared to extramedullary solitary plasmacytoma patients. On univariate analysis, bone disease and size (≥5cm) impacted negatively on PFS (P=0·0027 and P=0·04, respectively). Bone disease also affected OS (P=0·04). In multivariate analysis bone location was the only independent prognostic factor for PFS (P=0·0041) and OS (P=0·021). Patients with bone solitary plasmacytoma have a significantly worse prognosis than extramedullary solitary plasmacytoma cases.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.